Publications by authors named "Johan Holst"

Claim this Profile
A
Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages.
Megan L Heinrich, Matthew L Boisen, Diana K S Nelson, Duane J Bush, Robert W Cross, Johan Holst

Sci Rep· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Developing vaccines against epidemic-prone emerging infectious diseases.
Valentina Bernasconi, Paul A Kristiansen, Mike Whelan, Raúl Gómez Román, Alison Bettis, Johan Holst

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing vaccines against epidemic-prone emerging infectious diseases.
Valentina Bernasconi, Paul A Kristiansen, Mike Whelan, Raúl Gómez Román, Alison Bettis, Johan Holst

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring Vaccine Hesitancy Through an Artist-Scientist Collaboration : Visualizing Vaccine-Critical Parents' Health Beliefs.
Kaisu Koski, Johan Holst

J Bioeth Inq· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway.
Johan Holst, Maurizio Comanducci, Stefania Bambini, Alessandro Muzzi, Sara Comandi

Vaccine· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.
Johan Holst, Philipp Oster, Richard Arnold, Michael V Tatley, Lisbeth M Næss

Hum Vaccin Immunother· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for controlling invasive meningococcal disease in high income countries.
Johan Holst, Hanne Nøkleby, Julie A Bettinger

Vaccine· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease.
Lee H Harrison, Stephen I Pelton, Annelies Wilder-Smith, Johan Holst, Marco A P Safadi

Vaccine· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2nd international workshop on Neisseria vaccines (Neisseria vaccines 2009).
Belkis Romeu, Elizabeth González, Concepción Campa, Johan Holst, Oliver Pérez

Expert Rev Vaccines· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
Johan Holst, Diana Martin, Richard Arnold, Concepcion Campa Huergo, Philipp Oster

Vaccine· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
Johan Holst

Hum Vaccin· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
Muhamed-Kheir Taha, Maria Leticia Zarantonelli, Jean-Michel Alonso, Lisbeth Meyer Naess, Johan Holst

Vaccine· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contributions of the Norwegian Institute of Public Health to the development of vaccines against serogroup B meningococcal disease.
Einar Rosenqvist, Johan Holst, Hanne Nøkleby

Vaccine· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants.
Helvi Holm Samdal, Hilde Bakke, Fredrik Oftung, Johan Holst, Inger Lise Haugen

Hum Vaccin· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
Johan Holst, Berit Feiring, Lisbeth M Naess, Gunnstein Norheim, Paul Kristiansen

Vaccine· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunisation schedules for non-replicating nasal vaccines can be made simple by allowing time for development of immunological memory.
Hilde Bakke, Torhild N Setek, Phuong N Huynh, Inger Lise Haugen, E Arne Høiby, Johan Holst

Vaccine· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bordetella pertussis can act as adjuvant as well as inhibitor of immune responses to non-replicating nasal vaccines.
Anita Haugan, Phuong Xuan Thi Dao, Nina Glende, Hilde Bakke, Inger Lise Haugen, Johan Holst

Vaccine· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can nonliving nasal vaccines be made to work?
Bjørn Haneberg, Johan Holst

Expert Rev Vaccines· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outer membrane vesicles from Neisseria meningitidis.
Mohammad Reza Mirlashari, Ernst Arne Høiby, Johan Holst, Torstein Lyberg

APMIS· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis